Top 5 Kidney Support Supplements of 2026 – Clarity MD
The two chiefs
House chief · 5/10
comparison listicle advertorial on the seller's own store · pre-sell behind organ-category search and creative · adults 55+ shopping for kidney supplements who may not know the ingredient · problem-aware moving to solution-aware · no named mechanism; oxidative stress as the cause, a three-part standard as the test
Lead: Category-dismissal deck, then the problem-solution lead (entries 3, 7-11). Grade B for the deck, C for the seam at entry 8, where the ingredient is presumed known.
Offer: Simple and strong: $29.99, a first-order discount, free shipping, ninety days to claim a refund. The price is stated three times and the guarantee five. No bundle detail, no bonus, no reason for the discount.
Close: Three links that escalate from a look to a trial, the last carrying the guarantee (entries 31, 63, 66). The recap rests on the tester's claimed personal use (entry 56). Urgency is mild and unproven.
Throughline: Worry to vindication in the first tenth, carried by the organ; then the kidneys disappear for five cards and return only in the recap. A reader who came for kidney supplements has to accept the narrowing to one ingredient twice: in the deck, then again at the list title.
Strongest
- The category-dismissal deck (entry 3).
- A headline tease paid back in the winner's card (entries 2, 24).
- Criteria before candidates (entries 12-16), with the count of yardsticks now stated honestly as four.
- Generous rival cards with commercial markdowns (entries 33-36).
Weakest
- Hook and body do not match: a category is promised and one ingredient is ranked (entries 2, 16).
- An organ promise with no organ evidence, and one research claim with no study (entry 27).
- No evidence of the test: no photographs, dates, lab values or scoring sheet (entries 16, 17).
- A narrator with no credential and a publication named only in the footer (entries 4, 67).
Craft chief · REVISE
The deck is the best opening of the four, and it writes a cheque the list cannot cash: the reader is promised kidney supplements and handed five bottles of one ingredient.
Strongest
- Entry 3: a first sentence true to the search experience, then the whole category dismissed in favour of one researched ingredient.
- Entries 2 and 24: a tease and its payback in matching words.
- Entries 52-53: the one outright failure argued with division.
Weakest
- Entry 2 against entry 16: a category promised, a single ingredient delivered.
- Entry 8: the ingredient presumed familiar to a reader who was never introduced to it.
- Entry 27: a claim about kidney research with no study behind it.
- Entry 46: two cons fault the dose the page itself calls the standard.
- Entries 37, 43 and 49: another publisher's small print left in the template.
001 PASS·noted: entries 9 and 64 have real cadence; entries 25 and 28 are lists in sentence clothing · 002 PASS: attention (2-3), belief (7-16), desire (17-29), action (31, 63, 66); the links escalate from a look to a trial · 003 PASS: plain words throughout; one unexplained technical word at entry 14 · 004 REVISE: flat spots at entries 44-49, where card four has no argument; entry 46 undoes the first criterion (entry 13); about sixty percent of the page passes between links (31 to 63) · 005 REVISE: the headline (2) promises a survey of kidney supplements and the list holds five bottles of one ingredient; the deck (3) makes the switch in a single sentence, and the list title (entry 16) contradicts the page title · 006 PASS·noted: exact prices and doses carry the cards; the grades (17, 32, 38) have no method and the discount at entry 22 has no reason-why · 007 PASS·noted: capitals at entry 14 stress a phrase the voice would not shout · 008 PASS·noted: the winner's case is made five times (18-19, 25, 27-29, 57-59, 64); useful to scanners, heavy for readers · 009 N/A: the lead is problem-solution in the first person, not a story · 010 PASS: entries 9-11 and 41 sound spoken · 011 PASS·noted: one picture row (6) with no alt text; the grades of cards four and five are not in live text (44, 50) · 012 REVISE: entries 37, 43 and 49 ship another publisher's small print; the first tab (5) names a section the page does not have · 013 PASS: entry 3 starts from what the shopper has already met in search results · 014 PASS·noted: the arc is frustration, vindication, confidence; it peaks at entry 10 and does not return to feeling until the loss line at entry 65 · 015 PASS·noted: one throat-clearing opener (10) and one mirrored contrast (61); noted, not a fault in a competitor's page · 016 REVISE: the ingredient is withheld from headline and deck, then presumed familiar at entry 8; a supplier's extract name appears untaught at entries 39 and 46 · 017 PASS·noted: curiosity is strong (a single survivor, entry 2) and is paid back at entry 24; stakes ride on the deck; emotion has no carrier · 018 PASS·noted: color lives in the first sentence of the deck (3), the image of daily filtering (8), the fallback line (36) and the dose arithmetic (53) · 019 N/A: not founder copy; the tester is a persona with no supplied voice · 020 REVISE: the same body runs under four titles on the store, with the five cards cloned word for word · 021 N/A: no email sequence in scope · 022 PASS: nothing sharp was marked down for being bold; claim worries are listed under leave, not in these verdicts · 023 PASS: the first screen names what the reader leaves with, the deciding factors and a ranking · 024 N/A: no product verb claims a decision that belongs to the buyer · 025 PASS·noted: five products in the headline (2) become fifty-plus at entry 56; a four-minute read is printed on a page of about 1,900 words (4)
Take
- The category-dismissal deck (entry 3): name what the shopper has already met, then set one researched ingredient against it.
- A headline that teases a single survivor and is paid back in matching words in the winner's verdict (entries 2, 24).
- The count of yardsticks stated openly in the method line (entry 16), so argued and scored criteria agree.
- The organ overlay: 14 rows out of 152 carry a single organ through an unchanged ranking; the organ appears only where the seller speaks in its own voice.
- Criteria before candidates: problem (entries 7-11), three named tests (12-15), one line of method (16), then the cards. The reader accepts the yardstick before learning who benefits from it.
- Winner first, about a sixth of the way down (entry 17), not held back for a countdown; every later card is read against it.
- The winner's first three pros mirror the three criteria in the same order (entry 18); trust points next, then guarantee, crowd and price last (entries 19-22).
- Generous rival cards: each rival is granted what it truly passes and is marked down on price and terms (entry 34). Only the last rival fails a criterion outright (entries 52-54), which proves the yardstick bites.
- Rival cards that send the reader back to rank one: the fallback line at the foot of the runner-up's card (entry 36) and the upward pointer at the foot of the value card (entry 42).
- The link ladder: two soft links (entries 31, 63) and one hard link with the guarantee in its wording (entry 66); no link inside any rival card.
- A re-crowning recap directly under the last rival (entries 56-60): heading, ticks in criteria order, the name last.
- Proportion as argument: nine pros and two cons for the winner, three pros and seven cons for last place.
- A three-beat second-person mirror of the failed purchase (entry 9), placed after the ingredient is cleared and before any blame is assigned.
Leave
- A title that promises a category and a list that holds one ingredient (entries 2, 16). Our rivals are the same species of product and the title says so.
- A dismissal of rival categories with no evidence (entries 3, 7); we state what ours has.
- A claim that kidney research used this dose, with no study behind it (entry 27).
- The ingredient presumed familiar to a reader who was never introduced to it (entry 8); most of our market has not met astaxanthin (p7).
- The claimed months of testing and the claimed personal use (entries 3, 56); treat as invented.
- The tester: a byline with no credential or trace (entry 4), a test with no data, dates or photographs (entry 16), a pool that grows from five to more than fifty (entry 56). Treat all three as invented.
- Letter grades with no scoring sheet (entries 17, 32, 38), missing altogether on cards four and five (entries 44, 50).
- Another publisher's small print under the rival cards (entries 37, 43 and 49) and a publication named only in the footer (entry 67).
- Cosmetic and contradictory cons: plain packaging and no bonus ingredients (entry 40); the standard dose listed as a drawback (entry 46).
- Their delivery criterion (entry 15): an oil-against-powder superiority claim is banned for us (b8).
- Crowd and doctor claims with no source (entries 21, 26); our numbers wait for a measured panel (r17) and a named quote (r19).
- Their ninety-day window and first-order discount wording: our offer is BRAND section 3 and the 30-Day Money-Back Guarantee.
- Sold-out scarcity (entries 23, 36) unless a true stock statement exists.
- A verdict with no point of view and praise that contradicts placement (entries 47, 48).
- An unnamed felt result (entry 62): we name what the reader notices and in which weeks, from the gate.
Line by line · 68 entries
Every line is described in our words; the page's own text stays on the page (open it beside this table). Shaded rows carry the most pull.
| # | Beat | What the line does | Lever · reader | Why here | Craft | On our page |
|---|---|---|---|---|---|---|
| 1 0.2% | disclosure cta · 2 w | A two-word link at the very top marks the page as advertiser-funded. The terms sit behind the click; nothing on the page itself says who pays or who owns the winner. | candor problem-aware | It stands above the headline because that is where review publishers put theirs. A reader who meets it first files the page under comparison sites before any claim is made; placed after the pitch it would read as a confession. | Two words, no sentence. It works as costume more than as disclosure: the store that publishes the page also sells the product ranked first, and no line says so in plain words. | page-furniture CS-P1 has no disclosure link at the top; its 'Advertorial' byline tag was removed on 2026-09-15 and the supplement disclaimer sits in the footer. Whether a top-of-page disclosure returns is David's call. If it does, it names CellScience in plain words. |
| 2 0.8% | hook-headline h1 · 12 w | The first-person test of five is now said to be of kidney support supplements, a category, and the payoff becomes a tease that a single product passed every check. The ingredient is not named. | curiosity-gapearned-authorityspecificityexclusivity problem-aware | The entry point is one rung lower than on the other titles: the reader knows the worry and the category, not the ingredient. The headline keeps the ingredient back so the click is not lost on an unfamiliar word; the deck has to introduce it at once. | Twelve words. The second half changes from a promise of criteria to a promise of a winner, a stronger pull and a bigger debt: every product in the list turns out to be the same ingredient. The headline promises a category the page does not survey. | rewrite-claim CS-P1's H1 names the ingredient and four organs. An organ-category title is a hook to test, but only if the list is honest about being astaxanthin products: our rivals rule (CL-13) is same species. Kidney wording rests on r10 and r26. r10r26 |
| 3 2.0% | deck p · 36 w | The deck names three rival kinds of kidney product as what search results are full of, sets against them a single antioxidant with published research, and claims months spent testing which brands carry a proper dose. | common-enemycontrastborrowed-authorityearned-authority problem-aware | It has to follow the headline immediately: the headline promised a category and the list will deliver one ingredient. This is the sentence that makes the switch, before the reader has seen any product. | Two sentences, thirty-six words. The first is concrete and true to the search experience, the best opening line of the four titles. The second does three jobs at once and strains. The ingredient is still unnamed on the first screen. The months of testing are unsupported; treat as invented. | rewrite-claim The move transfers: name what the kidney shopper has already met, then the ingredient that has studies behind it (r14, r15) and why it suits kidneys (r10, r26). We state what ours has; we do not claim the alternatives do nothing. CS-P1 has no category-dismissal line. r14r15r10r26 |
| 4 3.7% | authority-stamp 2× p · 12 w | A bare byline with a woman's name, then an updated date in July 2026 and a four-minute reading time. No title, no credential, no publication beside the name. | earned-authorityease solution-aware | It follows the deck because the 'I' of the headline needs a name before the argument starts. The date tells the shopper the ranking is current for the year in the page title. | Thin. A name with nothing behind it asks for trust in a stranger, and the reading time undersells a page of about 1,900 words. No bio, no link, no trace of her elsewhere: treat the tester as an invented persona. | keep-structure CS-P1 already carries a heavier stamp: a named health editor with sixteen years on the beat, a headshot, a date, a nine-minute read and a press strip. Our editor is a generated persona as well (BRAND log 2026-09-14), so the same question of disclosure applies to us. |
| 5 4.4% | page-furniture 3× p · 5 w | Three jump tabs sit under the byline: one for benefits, one for dosing, one for the ranked list. | ease solution-aware | Placed above the hero picture, where a news site keeps its section links. It previews the order of the page (science, then list) before the reader has scrolled. | One or two words per label. The first tab promises a benefits section the page never writes: benefits get a single sentence in the intro. | page-furniture CS-P1 has no jump tabs; its chassis uses a sidebar showcase and a sticky bar instead. Not needed unless scroll data shows readers hunting for the list. |
| 6 4.9% | image img | A wide, shallow hero picture spans the column. It has no alt text, so the rows cannot say what it shows. | none solution-aware | It follows the byline and tabs and comes before the first subhead, the usual place for an article's lead picture. The opening argument therefore begins below the first screen. | It is the only picture in the extract. No product photograph in the five cards was large enough to be captured, if any exists. For a page that claims hands-on testing, no picture of a product in hand is the loudest gap. | keep-structure CS-P1's hero is our own bag with a caption calling it the top pick, so our winner is revealed on the first screen; this page keeps its hero neutral and holds the winner back until the list. A neutral hero (the five rivals side by side) is a test worth boarding. CS-P1 already shows a branded still in every rival card. |
| 7 6.3% | failed-solutions h3 · 7 w | The first subhead says the bulk of kidney supplements have no effect, and implies the reason is coming. | curiosity-gapcommon-enemyidentification solution-aware | Before any science, the page tells the reader that a flat result is normal for the category they searched. It has to come ahead of the criteria, because the criteria are sold as the explanation. | Seven words, the bluntest of the four versions. It indicts a category the page never examines: no kidney supplement other than astaxanthin appears below. | rewrite-claim We cannot indict a category we have not examined. Our version gives the reason a supplement can burden or spare the kidneys: water-soluble vitamins are flushed through them, astaxanthin is fat-soluble and settles into cell membranes (r26, r5). CS-P1 says this in its winner card and FAQ, not in a subhead. r26r5r10 |
| 8 7.2% | proof-study p · 41 w | The ingredient is named for the first time, as something the reader has likely heard of. The count of more than 70 studies is tied to oxidative stress, described as the daily wear of filtering on the kidneys. | loop-closedborrowed-authorityfear-of-decline solution-aware | This is where the ingredient finally gets its name, a fourteenth of the way down. The deck's unnamed antioxidant was an open loop and this closes it, ahead of the flat-result line. | The opening assumes familiarity with an ingredient the headline and deck withheld: for the category shopper that is a jolt, a seam left by the edit. The closing image of daily filtering is the most physical line in the intro. No kidney study is named. | swap-proof We have the same enemy cleared (r1) and the kidney pillar (r10), with 60+ studies as the count (r14). Most of our market has not met astaxanthin (p7), so our line introduces it and does not presume it. CS-P1's intro does introduce it, by contrast with vitamins. r1r10r14p7 |
| 9 8.4% | symptom-mirror p · 16 w | Three clipped second-person beats replay a purchase: the bottle, the months, no change felt. | mirroringidentificationcommitment solution-aware | With the ingredient cleared, the page turns to the reader's experience, so the gap between a proven ingredient and a flat result becomes a puzzle. One line earlier it would have read as an attack on the ingredient. | Close to the base page, with the pause removed and the letdown put in terms of feeling. Sixteen words. For a reader who came for kidney supplements the bottle is unspecified: it can be read as any kidney product. | keep-structure CS-P1 has no second-person replay of a failed purchase; its intro speaks of what the reader was told to take. A three-beat mirror about the cabinet of vitamins fits our reader in their 60s and 70s (r3, r23). r3r23 |
| 10 8.9% | villain-reveal p · 35 w | The writer clears the ingredient and blames products that supply too little, in a form the body cannot absorb, so the ingredient never arrives at the filtering organs. | vindicationcommon-enemyreason-why solution-aware | It answers the puzzle the previous line opened. Criteria can only be introduced now, because a test needs a fault to look for. The blame falls on a whole category, so every rival below starts under suspicion. | Dose enters the blame ahead of form. The second sentence chains three conditions with commas and ends on a paraphrase for the kidneys, which avoids repeating the organ's name. | rewrite-claim Our honest villain is the unverified label: about 64% of unverified astaxanthin products fail potency testing (c1), and many brands sell 4 to 6 mg (b7). What reaches the cell is ours to explain (r5). CS-P1 holds the first two in its method box and the third in its intro. c1b7r5 |
| 11 9.8% | turning-point p · 26 w | The writer says her own study reading surfaced three deciding factors for a kidney supplement, and pictures the failing product as passing through the body. | earned-authorityopen-loopspecificity solution-aware | It is the hinge of the top third. The villain is named, so the reader now wants the test for it, and the count of three promises the test is short. It has to precede the list or the grades would have no yardstick. | Identical to the base page except for the product noun. The three factors that follow concern one ingredient, so the sentence promises a category-wide test it cannot give. | keep-structure CS-P1 has this hinge in the editorial plural: five products bought, every label read, three things ranked. Ours rests on reading each rival's own page on a stated date, which is true. One mismatch to fix: CS-P1's subhead says three tests and its method box lists five things; this page holds the count at three until the scoring line. |
| 12 10.8% | ranking-criteria h2 · 9 w | A section heading presents three factors as requirements for any product in the category. | specificityreason-why solution-aware | It sits between the problem and the list, so the yardstick is accepted before the reader knows who profits from it. A reader who agrees here has half agreed with the ranking. | Nine words with a number and a verb of obligation: the register of a buyer's guide. | keep-structure CS-P1 has a method box headed as five deciding things. Keep it, but let the heading count match the three score bars on every card (the full 12 mg in one softgel, third-party lab tested, cost per day). b7c1 |
| 13 11.8% | ranking-criteria h3 · h4 · 7 w | Criterion one is dose, with 12 mg named as the amount clinical work uses. Only the title shows; the explanation is folded away. | anchoringborrowed-authorityspecificity solution-aware | Dose goes first because it is the easiest thing to check on a label and the one test the last-placed rival will fail. The first criterion frames how the other two are read. | Six words. The phrase borrows the authority of trials without citing one. With the body collapsed, the claim is asserted, not argued. | keep-structure CS-P1 already leads its method box and its score bars with this: the full 12 mg in one softgel, the dose the human trials used (b7, b9). b7b9 |
| 14 12.4% | ranking-criteria h3 · cta · 6 w | Criterion two is origin: natural microalgae, tied in capital letters to how well the body can use the ingredient. The explanation is again folded away. | reason-whycontrast solution-aware | After quantity comes quality: once 12 mg is accepted, the next doubt is whether all 12 mg are equal. Source precedes delivery because delivery only matters if the raw material is right. | The capitals shout where the first criterion spoke; the inconsistency looks like an unfinished template. The one technical word in the top third goes unexplained on the surface. | keep-structure CS-P1's method box has this criterion and says openly that all five rivals pass it, so it did not decide the ranking: a candor move this page lacks. Rests on natural microalgae as the form the human studies used (c4), synthetic made from petrochemicals (r16), closed bioreactors (c5). c4r16c5 |
| 15 12.9% | ranking-criteria h3 · cta · 6 w | Criterion three is format, set up as a contest between oil-filled softgels and dry powder capsules. | contrastreason-why solution-aware | Last of the three because it is the least intuitive: the reader needed dose and source first to care how the dose travels. It closes the loop the intro opened about a form the body can use. | Five words built on a versus. No product in the list is a dry powder, so this criterion eliminates nobody on the page: it explains the intro and sorts nothing. | rewrite-claim A carrier-oil or oil-format superiority claim is banned for us (b8). What holds: astaxanthin is fat-soluble (r26) and is taken with a meal that has some fat (r31). CS-P1 does not use a delivery axis; its second bar is third-party lab tested (c1, c3), the test that does separate our product. r26r31c1c3 |
| 16 13.6% | ranking-criteria h2 · p · 38 w | The list title still names the ingredient, not the organ. The method sentence now counts four yardsticks openly and ties them to whether the kidneys gain: the three criteria plus value. | specificityearned-authority solution-aware | It stands at the threshold of the cards. It is the last organ mention for a long stretch: the cards that follow are identical to the base page, so this line has to carry the kidney frame across five generic cards. | The count of four is stated, which repairs the base page's mismatch of three argued criteria and four scored. The list title contradicts the page title: one says astaxanthin, the other kidney support. The test is asserted and never shown; treat it as unverified. | keep-structure CS-P1 states its method more fully (five points, each with its reason, including the 64% figure, c1) and shows scores per axis. Keep ours. Worth taking: one plain sentence of method directly above the first card. c1b7 |
| 17 15.5% | ranked-entry h2 · h3 · 2× p · 9 w | Card one names the seller's own 12 mg product as rank one, gives the maker line and stamps it with the top letter grade. This is the product reveal. | anchoringearned-authority solution-aware | The winner comes first, about a sixth of the way down: a shopper who reads one card reads this one, and every later card is judged against it. The criteria just above make the grade feel derived. | Four rows, nine words. A letter grade is a shrewd unit: everyone has been graded at school, and a letter hides the absence of a scoring sheet. No sub-scores appear; the grade has no stated method. | keep-structure CS-P1 already ranks our product first, with a ribbon and three numeric score bars. Ours is the stronger form because the axes are visible. Name it as CS-P1 does: CellScience Astaxanthin 12mg, The Cell Shield. |
| 18 17.6% | ranked-entry h2 · 3× p · 39 w | The first three plus points restate the three criteria in the same order (dose, source, delivery), each with a short reason after a colon. | loop-closedreason-whyspecificity product-aware | They lead the list while the criteria are still fresh; the matching order makes the grade look like arithmetic. Any other order would hide the fit. | Label, colon, reason: a mould a skimmer reads in two seconds a row. The first reason slips into the first person, which keeps the tester in the room. Row two holds the only named place of origin for an ingredient on the page. | keep-structure CS-P1's winner pros open with dose and testing, matching its first two score bars (b7, b9; c1, c3); the third bar, cost per day, has no pro. Origin follows (c4, c5). Whether a cost-per-day pro returns to the card is David's call (price line removed 2026-09-15). No oil claim (b8). b7b9c1c3c4c5 |
| 19 19.6% | ranked-entry 3× p · 37 w | Three trust points follow: outside-lab checks of purity and strength, a free-from label, and domestic manufacture in a certified facility. | borrowed-authorityobjection-preempt product-aware | With the formula accepted, the next question is whether the label can be believed. These come before the money points so that price is read as a bonus on a sound product. | Same mould. No lab is named, no report linked, no batch number given: testing is claimed in a phrase. The free-from row is three hyphenated adjectives in a line. | swap-proof Here our page is the stronger one: every batch third-party lab tested (c3, worded as 'lab tested' per the 2026-09-15 verdict) in a category where about 64% of unverified products fail (c1). Badges per r18: cGMP, Made in USA, gluten-free; vegan only if the shell is. CS-P1 has the testing line and no badge row in the card. c1c3r18 |
| 20 21.2% | guarantee p · 9 w | Plus point seven is the refund window: ninety days, with the promise put as a plain either-or. | risk-reversal product-aware | It follows the trust points and precedes crowd and price: a reader burned by one flat bottle needs the exit before the numbers. Inside a pros list a guarantee reads as something the tester found, not a sales promise. | Nine words. The second half is a slogan with rhythm: two short clauses joined by a conjunction. | swap-offer Ours is the 30-Day Money-Back Guarantee, keep the bag (BRAND section 3; the gate's 90-day wording in r22 is superseded by the lock of 2026-09-12). CS-P1's winner pros already end on it. |
| 21 21.7% | proof-social p · 12 w | Plus point eight joins an unnamed medical endorsement to a customer count above 142,000 and a rating of 4.8 on a five-point scale. | social-proofborrowed-authorityspecificity product-aware | Crowd proof lands after the guarantee and just before price: the reader has the facts and the exit and now learns they would not be alone. It is the only social proof until the verdict repeats it. | Label and reason do not match: the label promises doctors, the reason gives customers. No doctor is named and no review platform cited. Count and rating have no source; treat both as unverified. | swap-proof CS-P1 shows a customer count and rating in its sidebar and a comment thread that is still placeholder text (a launch blocker). Our cleared routes are the consumer-panel block once it has run (r17) and the longevity-doctor quote (r19). No number before it is measured. r17r19 |
| 22 22.1% | offer p · 15 w | The last plus point is price: $29.99 for today, a first-order discount of up to 70 percent and free domestic shipping. | anchoringurgency product-aware | Price closes the list: eight reasons first, the number last. Stated inside card one, it becomes the reference every rival price below is measured against. | Three offers in fifteen words. Two time words hint at a deadline without stating one. The discount ceiling and the single price do not add up on their face, and no reason for the discount is given. | swap-offer Ours: one bag $29.99, three bags $59.97, five bags $89.95, free shipping on every tier (BRAND section 3; the five-bag tier carries x4). CS-P1 took the price line out of the winner card on 2026-09-15 and states price in the CTA block. This page shows what an in-card price does to the rival cards below; David's call. x4 |
| 23 22.7% | ranked-entry h2 · 2× p · 20 w | The winner's two minus points: it is sold only through the maker's own site, and multi-packs run out during sales. | candorexclusivityscarcity most-aware | A pros list with no cons would break the review format. They follow the price, so the first thing the reader does with the price is worry about availability. | Two rows against nine. Neither is a fault in the product; both are reasons to act now. It is the oldest device in the format and a careful reader will see through it. | keep-structure CS-P1's 'worth knowing' block has the same two (official site only, r29; launch pricing on the multi-bag tiers) and adds a real limit: it is a daily supplement, not a treatment. Keep the real limit first; it is what makes the block believable. r29 |
| 24 24.3% | ranked-entry h3 · p · 29 w | The tester says this product alone needed no trade-off, and tells the reader who came for kidney support that the product passes every check. | earned-authoritycontrastloop-closed most-aware | Lists persuade skimmers; a judgement in a voice persuades readers. It follows the cons so the last word on the product is the tester's and not the drawbacks'. | The second sentence echoes the headline's closing phrase, so the tease made at the top is paid in the first card. A tidy callback. | keep-structure CS-P1 has this as a boxed paragraph explaining the top spot: the only product that passes all three tests at once, with the kidneys named in the paragraph under it (r26). A callback to the headline's promise is worth taking. Keep ours. b7c1c3r26 |
| 25 25.5% | differentiation 2× p · 62 w | Two paragraphs replay the formula and the trust points as prose: dose, softgel and algae origin set against cheaper synthetic product, then testing, facility and label named as what settled it. | contrastcommon-enemyreason-why most-aware | The repetition is deliberate: the page is built so that a reader entering at any point meets the three criteria. The swipe at synthetics is safe here because none of the four rivals below is synthetic. | It sags. Both paragraphs are lists in sentence clothing, thirty-one words each. The one lively phrase is the jab about petrochemicals; a short idiom of decision keeps the voice alive. | swap-proof CS-P1's winner body does this in two paragraphs with our facts: natural microalgae (c4), closed bioreactors (c5), fat-soluble so less for the kidneys to handle (r26), and the organs named. The contrast with synthetic product is cleared (r16). c4c5r16r26 |
| 26 27.8% | proof-social p · 43 w | The verdict ends on numbers: the customer count, the rating and the doctors again, then the routine (one softgel daily, thirty in a pouch) and the ninety-day window. | social-proofeaserisk-reversal most-aware | The crowd comes last in the verdict, so the personal judgement is backed by numbers just before the bottom line restates the deal. | Forty-three words, the longest paragraph in the card, and it changes subject twice. Its opening clause admits the numbers are there as backup, which is honest about their job. | swap-proof Ours: one softgel a day with a meal (b9, r31), thirty to a bag, the 30-Day Money-Back Guarantee. Crowd numbers only once measured (r17). CS-P1 has the routine and the guarantee in the winner pros and no crowd line in the card. b9r31r17 |
| 27 28.8% | differentiation h3 · p · 31 w | A bottom-line label, then a contrast: many brands cut corners on each criterion, and this one is pitched at buyers after the dose that kidney research used. | common-enemycontrastidentification most-aware | A second summary label inside one card gives the scanner another entry point. It turns the criteria from tests into accusations just before the price is repeated. | The contrast now ends on a research claim: that kidney studies used this dose. No such study is named anywhere on the page. Treat the claim as unsupported. | rewrite-claim We may say brands underdose at 4 to 6 mg (b7), that synthetic astaxanthin is made from petrochemicals (r16) and that most unverified products fail potency tests (c1). We do not tie 12 mg to kidney trials without the citation in hand. CS-P1 has no second summary inside the winner card. b7r16c1 |
| 28 30.2% | offer p · 34 w | One sentence stacks the three criteria and then the deal: today's price, the first-order discount and free shipping. | anchoringreason-why most-aware | Second statement of the price, now in a sentence that leads with value. It sits three rows above the link, so the deal is the freshest thing in mind at the click. | Thirty-four words in a single sentence that reads like a list with commas. A two-word pivot marks where it turns from product to price. | swap-offer CS-P1 keeps price out of the winner card (David's edit of 2026-09-15) and puts the per-bag price of the five-bag tier in the CTA block under it. Same slot, one step lower on the page. x4 |
| 29 31.3% | guarantee p · 40 w | The card's last paragraph notes the absence of fillers, restates the ninety-day refund and argues that the window is long enough for a fair trial. | risk-reversalreason-whyobjection-preempt most-aware | The guarantee is the last argument before the link because the doubt left, after one flat bottle, is whether this one will differ. Giving the ninety days a purpose answers how long until the reader will know. | Three sentences. The filler point is a stray that belongs with the label claims. The final sentence gives the guarantee a job, which most guarantee copy forgets. | swap-offer 30-Day Money-Back Guarantee, keep the bag. Our window is shorter, so its reason is what shows inside thirty days: steadier energy in weeks one to two (r7), eye strain relief in 14 to 28 days (b6). CS-P1 says this in its FAQ and timeline, not in the winner card. r7b6 |
| 30 32.5% | disclosure fine · 25 w | Small print under the winner's card says outcomes reflect individual users and are not typical, and refers the reader to the product's own site. | none most-aware | It sits between the last argument and the link in the smallest type on the page: present for a regulator, invisible to a reader moving toward the click. | Boilerplate of twenty-five words. It speaks of users' experiences although the card quotes no user. | page-furniture CS-P1 carries the supplement disclaimer once, in the footer. No per-card small print is needed. |
| 31 33.5% | cta p · 5 w | The first link out: a low-pressure invitation to read more about the winner, with an arrow. It asks for a look, not a purchase. | commitmentease most-aware | It stands at the end of card one, a third of the way down: the first point at which the whole case (criteria, grade, price, guarantee) has been made once. Any earlier and the review pose would break. | Five words and a plain verb. Keeping the word for buying out of the link keeps the page in character as a review. | keep-structure CS-P1 already places its primary CTA block directly after the winner card, with a harder button that carries the guarantee. A softer text link in the same slot is a test, not a gap. |
| 32 34.6% | ranked-entry 2× h2 · 2× p · 9 w | Card two names Rovina's 12 mg product at rank two with the next grade down, a single step below the top. | contrastcandor product-aware | It follows the winner's link: the reader who did not click now sees that the reviewer can praise a competitor. A near-equal second place is what makes first place believable. | The same four-row header as card one, so the eye compares like with like. The gap is one grade step. | keep-structure CS-P1 also has Rovina at rank two, marked down on its dose axis: four softgels a day to reach 12 mg, read on its own page on 2026-09-14. The two pages disagree on facts (this one says the count per bottle is not listed; we found sixty to a bag). Use only what we read ourselves. |
| 33 36.5% | ranked-entry h2 · 5× p · 32 w | Five plus points credit the rival with the full dose, algae origin, a coconut-oil base, a ninety-day refund and independent checks: it passes every criterion. | candorconsensus product-aware | Praise comes first: a rival that passes all three criteria proves the criteria were not rigged for one brand. It has to precede the cons so the markdown reads as fair. | Shorter rows than the winner's, five to seven words each, and nine rows shrink to five. The brevity is itself a ranking signal. | keep-structure CS-P1's rival cards each carry three pros, every one read from the rival's own page. Same move; ours is sourced. |
| 34 38.9% | ranked-entry h2 · 4× p · 27 w | Four minus points, none about the formula: a price near $39.99, best pricing tied to auto-ship, softgel count not shown, and online-only sales. | anchoringloss-aversioncontrast product-aware | The rival's price appears only after the winner's $29.99 has been stated twice, so ten dollars more needs no comment. Commercial cons keep the markdown defensible. | The mould again, six words a row. The online-only point is the same fact the winner's own cons carried as exclusivity: the page faults a rival for what it treats as a virtue in itself. | keep-structure CS-P1 marks Rovina down on routine (four softgels a day), supply (fifteen days to a bag) and test results available only on request, with price shown as a tier symbol. Ours is stronger because each con is a label fact. Do not borrow theirs. |
| 35 41.0% | ranked-entry h3 · 2× p · 104 w | The verdict praises the rival's fundamentals, places it just behind the winner on price and sales model, flags the missing softgel count and credits its refund window. | candorreason-whycontrast product-aware | The reader has seen equal formulas and needs a reason for unequal grades. The prose supplies it and names the winner again inside the rival's card. | A paragraph of sixty-six words, then one of thirty-six. Conversational and exact on price. It repeats the cons nearly item for item. | keep-structure CS-P1's rival bodies have the same shape: two paragraphs, praise first, then label facts. Already there. |
| 36 44.5% | ranked-entry h3 · p · 42 w | The rival's bottom line recommends it only as the fallback should the winner be out of stock, then repeats that it costs more but is an honest formula with a long refund window. | scarcitycandoranchoring product-aware | It closes the strongest rival's card, the point where a reader might defect. The fallback framing sends them back up the page, and no link to the rival is offered. | The opening conditional is the cleverest sentence in the rival cards: a recommendation that sells the other product. | rewrite-claim CS-P1's rival cards end on a price tier and a short verdict tag, not on a fallback line. The device transfers only with a true stock statement; we have launch pricing on the multi-bag tiers, not a stock limit. Without one, the pointer back to rank one is the part to keep. |
| 37 46.0% | disclosure fine · 22 w | Small print under the rival's card credits the results to a named ranking system that belongs to another review publisher: a leftover from the template this page was cloned from. | none product-aware | It sits at the foot of each rival card by template habit. Its content gives away the page's origin: the chassis of a third-party review site, reused by a seller. | A tell. The system it names appears nowhere else on the page, and the footer claims a different publisher. Treat the ranking system as nonexistent here. | drop Nothing to take. CS-P1's builder asserts that no donor string survives the purge; keep that assertion. |
| 38 47.3% | ranked-entry 2× h2 · h3 · p · 11 w | Card three names Double Wood's product at rank three, with a grade in the B band, one step below the runner-up. | contrast product-aware | By the third card the reader expects a drop. The step from the A band to the B band marks where nearly-as-good ends and good-for-the-money begins. | The same header mould. The grade ladder so far is evenly spaced, which makes it look computed. | keep-structure CS-P1's rank three is BioAstin; Double Wood is not in our list. Keep our own four rivals, each verified on its own page and each the same species of product (CL-13). |
| 39 49.2% | ranked-entry h2 · 4× p · 29 w | Four plus points: a full 12 mg of a branded extract, outside testing in a certified US facility, about $25.95 for sixty softgels, and a free-from formula. | candorspecificity product-aware | The lower price is admitted openly, two cards after the winner's price was set. The page has to deal with the bargain somewhere and does it mid-page, where fewer readers are. | The branded extract name appears unexplained; a stranger would not know it is an ingredient supplier. The price row is the most exact on the page: dollars, cents and count. | keep-structure CS-P1 concedes value openly in its Sports Research card (lowest cost per day on the list). Already there. |
| 40 51.4% | ranked-entry h2 · 5× p · 38 w | Five minus points, all cosmetic or circular: a plain bottle, no added vitamins, olive oil as the carrier, mostly direct sales, and no bonus ingredients. The second and fifth are one point stated twice. | contrastanchoring product-aware | The rival passed all three criteria and costs less for twice the count, so the markdown has to come from outside the criteria. The cons follow the price row at once, to blunt it. | The weakest list on the page. Packaging is not a criterion, and a single-ingredient formula is what the winner is too. A reader doing the arithmetic will see the winner costs more per softgel. | drop We do not invent cosmetic faults: CS-P1's rule is rival copy that is accurate and fair, every line read on the rival's page. Where a rival is cheaper, CS-P1 says so and wins on the lab-testing bar (c1, c3). c1c3 |
| 41 54.3% | ranked-entry h3 · 2× p · 87 w | The verdict admits surprise, credits the full dose at about $26 in an olive-oil base and the testing, and concedes only a plain bottle and no extra antioxidants. | candorspecificity product-aware | Mid-page, with the winner's case already made, generous praise costs little and buys trust for the final recommendation. | It opens on a three-word sentence with real voice, and the quip about looks is the only joke on the page. Thirty-two and fifty-three words: the praise outruns the criticism. | keep-structure CS-P1 does this in its value-pick card, which opens by granting that the rival would win on price alone. Already there. |
| 42 57.3% | ranked-entry h3 · p · 52 w | The bottom line calls the rival one of the best values listed and sends readers who care about extras or presentation back up the ranking. | candorcontrast product-aware | At the foot of the value card the page sorts readers by motive. The upward pointer is the only navigation cue inside the rival cards. | Four sentences, forty-nine words. The pointer is a quiet call to action with no link attached. | keep-structure CS-P1's cards end on a verdict tag with no pointer back to rank one. A one-line pointer at the foot of our value-pick card is worth adding. |
| 43 59.1% | disclosure fine · 22 w | The same leftover small print as under card two, crediting another publisher's ranking system. | none product-aware | Template position, the foot of every rival card. Repeated word for word, it becomes easier to notice with each card. | Identical to the line under card two. Repetition makes the borrowed chassis easier to spot. | drop Nothing to take; CS-P1 has no per-card small print. |
| 44 60.4% | ranked-entry h2 · h3 · p · 9 w | Card four names Sports Research's product at rank four. The grade label prints, but no letter reaches the text rows: the grade is an image or missing. | contrast product-aware | Fourth place is where attention is thinnest. The card is there to make five, and to hold a well-known retail brand below the winner. | From here the template frays: a label for the grade with nothing readable beside it. | keep-structure CS-P1 has Sports Research at rank four too, with three score bars in live text. Keep ours. |
| 45 62.3% | ranked-entry h2 · 3× p · 20 w | Three plus points, each a pair of claims: full dose in a triple-strength softgel, a vegan shell with coconut oil, and non-GMO verification with outside testing. | candor product-aware | Praise opens the card as in the two before it; by now the reader takes the pattern for fairness. | The separator changes from a colon to a middle dot, and each row packs two claims with no reason given. A different hand, or a different source, filled in this card. | keep-structure CS-P1's card for this rival has three pros read from its own page. Already there. |
| 46 64.2% | ranked-entry h2 · 5× p · 55 w | Five minus points: an unbranded algae extract, a daily cost above that of bulk tubs, a dose called more than occasional users need, storage that varies because many retailers carry it, and no lower-strength option. | contrastreason-why product-aware | With formula, price and testing conceded, only traceability and retail handling are left to fault. They appear in the fourth card, where scrutiny is lowest. | Two of the five contradict the page's own first criterion: the dose the page calls the standard is here a drawback. It is the clearest sign that the rival cards were filled in without reading the top of the page. | drop Nothing here transfers. CS-P1 marks this rival down on one thing: a tested badge with no batch report to open, against our third-party lab testing (c1, c3). c1c3 |
| 47 67.4% | ranked-entry h3 · p · 39 w | A one-paragraph verdict describes the product neutrally: full dose from algae in coconut oil, a plant-based shell that is rare among the five, sixty softgels for two months. | candor product-aware | The verdict slot has to be filled for the card to match the others; nothing here moves the reader. | It reads like a product listing. The first person vanishes for thirty-seven words. | keep-structure CS-P1's body for this rival has a point of view in both paragraphs (the value, then the missing report). Keep ours. |
| 48 69.2% | ranked-entry h3 · p · 72 w | The bottom line calls the product easy to trust, repeats its strengths, reduces the complaints to two minor ones and ends by recommending it to the majority of buyers. | candor product-aware | It closes a card that had little to say against the product. Its praise is affordable this low on the page, where few undecided readers remain. | Sixty-nine words, the longest paragraph among the rival cards, and it undercuts the rank: a product judged sound for nearly everyone sits fourth with no grade. Praise and position do not match. | drop A rank has to follow from the scores. CS-P1's three bars make each position checkable; do not take praise that contradicts placement. |
| 49 71.5% | disclosure fine · 22 w | The same leftover small print a third time, crediting another publisher's ranking system. | none product-aware | Template position, the foot of every rival card. | Identical to the lines under cards two and three. | drop Nothing to take; CS-P1 has no per-card small print. |
| 50 72.8% | ranked-entry h2 · h3 · p · 9 w | Card five names Life Extension's product in last place. Again the grade label prints with no letter in the text rows. | contrast product-aware | Last place is kept for the best-known catalogue brand: the biggest name falls furthest, which flatters the unknown winner. | The same frayed header as card four. | keep-structure CS-P1's rank five is Dr. Mercola, marked down on cost per day and on no test report on its page. Life Extension is not in our list. |
| 51 74.7% | ranked-entry h2 · 3× p · 42 w | Three plus points: an established name with quality control, phospholipids added to aid absorption, and a low price of about $12 a month. | candoranchoring product-aware | The low price is conceded first so that the cons can undo it. The reader has to hold the $12 figure in mind for the dose arithmetic that follows to bite. | The third row mixes a price with a remark about broad marketing, two unrelated points in sixteen words. | keep-structure CS-P1 grants each rival its real strengths before the facts that mark it down. Already there. |
| 52 76.9% | ranked-entry h2 · 7× p · 116 w | Seven minus points, the page's longest list: 4 mg a softgel against the 12 mg standard, a triple daily count to match it, a proprietary blend, a small bottle, a marine source, and a cost that climbs at full dose. | contrastreason-whyspecificityloss-aversion product-aware | The only outright failure is kept for last place. It is the payoff of criterion one: a familiar, cheap brand fails on dose, which proves the yardstick was worth learning. | The first two rows and the sixth are strong and arithmetical. Then the list pads: the rows on bottle size and softgel type are filler, and the last repeats a phrase from the pros. Seven rows against the winner's two is proportion used as argument. | rewrite-claim The contrast is cleared for us: 12 mg clinical strength against brands that sell 4 to 6 mg (b7). CS-P1's list has no underdosed rival, since all five are 12 mg products (CL-13), and its dose bar separates on softgels per day. An underdosed fifth card needs a same-species rival whose label we read ourselves. b7 |
| 53 82.2% | ranked-entry h3 · p · 78 w | The verdict trusts the brand and likes its absorption aid, then turns on the label number: 4 mg equals one third of the research dose, so it takes three softgels daily to equal one from the top picks. | reason-whyspecificitycandor product-aware | The list stated the fault; the prose proves it with division. It comes at the bottom of the ranking so that the last thing learned from the rivals is that dose decides. | Seventy-six words, the longest and best-reasoned paragraph on the page. It closes on a three-part sentence that pays two compliments before naming the fault. | keep-structure CS-P1 does the same arithmetic in its Rovina card (four softgels a day, a bag lasts fifteen days), from that rival's own directions. Already there. b7 |
| 54 84.7% | ranked-entry h3 · p · 55 w | The bottom line says the product does no harm, repeats that 4 mg is an underdose, and argues that the low-priced bottle stops being a bargain once enough softgels are taken to reach 12 mg. | anchoringreason-whyloss-aversion product-aware | It is the last rival sentence before the winner returns. Ending the ranking on the idea that cheap is not cheap shields the winner's price from the cheaper bottles in the list. | Fifty-two words. The closing clause points away to an unnamed elsewhere instead of naming the winner, which keeps the reviewer's tone. | keep-structure CS-P1 scores cost per day on every card, so the per-day arithmetic is already a bar, not a remark. Keep ours. |
| 55 86.6% | disclosure fine · 19 w | The small print changes for the last card: results are said to rest on what the product's own label and advertising state. | none product-aware | Template position, the foot of the card. It is the last line of the ranking proper, directly above the winner's return. | The one disclaimer that tells the truth about the method: the rival was judged from its label. It contradicts the headline's claim of testing. | keep-structure This is the honest version of the method, and it is ours: CS-P1 says in its intro that every label was read. Say it once, in the method, not in small print. |
| 56 87.7% | close h2 · p · 33 w | The heading re-crowns the product for the reader's kidneys. The tester enlarges her claim to more than fifty products and says this is the one she would take herself for that purpose. | earned-authorityexclusivityspecificity most-aware | At the foot of the ranking the reader has just seen the weakest product. The page brings the winner back at once, before attention drops, with a larger number that raises the cost of doubting. | Personal use is the new proof: the tester as customer. The pool still grows tenfold from the headline. Treat both as invented. | keep-structure CS-P1 ends on a final CTA block about the product that passed all three tests, after the timeline, comments and FAQ; it has no re-crowning section with a recap list directly under the last rival. Add one. The count stays at five, which is what we read. |
| 57 89.4% | differentiation 3× p · 25 w | The first three ticks repeat dose, source and delivery with bracketed reasons; the dose bracket now points to the amount used in research. | loop-closedreason-why most-aware | Third pass through the same three points: criteria, pros, recap. By now the reader can recite them, which is the aim: the yardstick has become their own. | One bracket edited to point at research: cleaner than on the sister kidney page, which doubled an adjective. | keep-structure Recap our three bars in their order: the full 12 mg in one softgel (b7, b9), third-party lab tested (c1, c3), cost per day. CS-P1 has a proof bar with three short items but no ticked recap beside the winner's name. b7b9c1c3 |
| 58 90.6% | differentiation 2× p · 15 w | Two more ticks: outside testing the buyer can verify, and a free-from label with no fillers. | borrowed-authorityreason-why most-aware | They follow the three criteria in the order the pros list used, so the recap reads as that list in miniature. | One bracket promises the buyer can check purity and strength, yet nothing on the page links to a report. The promise is not kept. | swap-proof Ours can keep the promise: third-party lab tested every batch (c3), against about 64% of unverified products failing (c1). CS-P1 states it in the winner card and the proof bar. c1c3 |
| 59 91.5% | offer 2× p · 17 w | The last two ticks are the ninety-day refund, described as time enough to judge, and the price of $29.99 with the discount ceiling. | risk-reversalanchoring most-aware | Third statement of the price and fourth of the guarantee. They close the checklist so the final items read before the brand name are the two that lower the cost of saying yes. | Eight and nine words. The label claims best value, although two products in the ranking cost less per softgel. | swap-offer 30-Day Money-Back Guarantee, keep the bag; $29.99 for one bag, $59.97 for three, $89.95 for five, free shipping (BRAND section 3, x4 on the five-bag tier). CS-P1's CTA blocks carry this; a recap list would restate it. x4 |
| 60 92.2% | close p · 4 w | A sentence of four words gives the brand's name as the answer to the checklist. | loop-closed most-aware | It comes after the ticks, not before, so the name arrives as a conclusion. The reader has known it since card one; the delay is for rhythm. | Short, flat, final. The reveal is cadence, not news. | keep-structure If we add a recap, it ends on the full noun: The Cell Shield, from CellScience. CS-P1's final heading alludes to the winner without naming it. |
| 61 92.7% | differentiation h2 · 2× p · 29 w | A heading promises what sets the brand apart. Two matched sentences: most brands are the work of marketers after margin; this one comes from a team that minds whether the ingredient arrives at the kidneys. | common-enemycontrastidentification most-aware | After the facts, a character argument. It is kept for the close because near the top it would sound like advertising; here it follows five cards of apparent fairness. | The mirror holds better than on the sister kidney page: thirteen words against twelve. The cell of the base page is replaced by the organ. | swap-mechanism Ours has a name for what they gesture at: The Cell Shield, astaxanthin spanning the whole cell membrane (m2, r5), with the kidney cells as one place it matters (r10). CS-P1 uses the name in the winner title and the buttons but never joins name and idea in one line. m2r5r10 |
| 62 94.3% | differentiation p · 30 w | One paragraph says every requirement is met on purpose, admits this costs more to produce, and claims it is the only route to a result the reader can feel. | reason-whycandorhope most-aware | The reason for the price comes after the motive and immediately before the link: the reader about to click gets an explanation for why a product this complete is not the cheapest on the list. | Thirty words. The cost admission is a classic reason-why. The felt result is the closest the page comes to promising an outcome, and it names none. | rewrite-claim Where they promise an unnamed feeling, the gate lets us name what the reader notices and when: steadier energy in weeks one to two (r7), eye strain relief in 14 to 28 days (b6), kidney labs re-drawn at weeks eight to twelve (r10). CS-P1 has this as its week-by-week timeline. r7b6r10 |
| 63 95.1% | cta p · 5 w | The second link out repeats the first word for word: a soft invitation to read more about the winner. | commitmentease most-aware | It follows the argument about what sets the brand apart, about sixty percent of the page after the first link. The long gap is the price of the review pose: no link sits inside or between the rival cards. | Identical wording builds no escalation; the harder ask is held for the last line. | keep-structure CS-P1 spaces its CTA blocks more evenly (after the winner, mid-page, at the end) and has a sticky bar, so our reader is never sixty percent of a page from a button. Keep ours. |
| 64 95.7% | close h2 · 2× p · 27 w | Under a final bottom-line heading, a conditional piece of advice (anyone taking the ingredient should take an effective dose), then the four requirements as four clipped fragments. | reason-whyspecificitycommitment most-aware | The close speaks about the category, not the brand, which returns the page to its opening pose as advice. Coming after the second link, it serves the reader who is still reading and so still undecided. | The four fragments are the best rhythm in the close: a number, a place, a format, a test, each ending on a full stop. The conditional opener is sixteen plain words. | keep-structure CS-P1's final paragraph names its three points in one sentence. Breaking them into fragments (12 mg in one softgel; third-party lab tested; one softgel a day) would read better aloud for our reader. Rests on b7, b9, c3. b7b9c3 |
| 65 97.2% | stakes p · 10 w | A single sentence warns that accepting a lesser product means wasted money. | loss-aversionloop-closed most-aware | It is the last sentence before the final link. The deck promised to separate working products from costly duds; this line closes that loop and leaves the reader with the cost of inaction. | Ten words, second person, no hedging. It is the only stakes line on the page and it is about money, not health. | rewrite-claim Our stake is a true number: about 64% of unverified astaxanthin products fail potency testing (c1), so an untested bottle is a coin toss. CS-P1's final paragraph ends on benefit and has no loss line. c1 |
| 66 97.9% | cta p · 7 w | The final link changes the ask: try the winner, with the ninety-day risk-free window written into the link itself. | risk-reversalcommitment most-aware | Only the last link asks for a trial; the two before asked for a look. The escalation is saved for the reader who has read everything and needs the risk removed, not more information. | Seven words. The verb of trying plus the window makes the guarantee the call to action. It is the strongest of the three links. | swap-offer CS-P1's buttons already follow this pattern with the noun in them (try The Cell Shield, risk-free). The 30-Day Money-Back Guarantee is named in the line under the button. |
| 67 99.6% | page-furniture fine · 8 w | A copyright line names a publication, Daily Health Report, as the rights holder for 2026. | borrowed-authority most-aware | The publication is named only here, in the last row, in small type. The top of the page shows a byline with no masthead, so the publisher's name is present for form and unseen in practice. | Eight words. The page lives on the seller's own store domain while the footer credits a news-style publisher: the two do not agree. Treat the publication as a label, not an outlet. | page-furniture CS-P1 has a full publication identity (The Healthy Aging Review) in masthead and footer, on its own prelander site. Already there, and consistent from top to bottom. |
| 68 4.7% | page-furniture fine · 5× li · 14 w | A store currency selector: the current currency code, an auto-location option and four currencies. It is store chrome, captured at the end of the extract although on screen it sits near the top. | none solution-aware | It belongs to the store's theme, not to the article: the rows report a position near the top of the page yet arrive last in the extract. It shows the page is a store page dressed as a publication. | No copy to judge. The selected code reflects the visitor's location at capture, not a choice of the writer. | page-furniture Nothing to take. CS-P1 lives on its own prelander site with no store chrome. |